EPISODE · Jul 24, 2024 · 36 MIN
Teaching Tolerance to Address Autoimmune Diseases
from The Bio Report · host Levine Media Group
The traditional approach to treating autoimmune disease has relied on ways to suppress the immune system. COUR Pharmaceuticals is developing first-in-class therapies that instead seek to reprogram the immune system to create antigen-specific tolerance. We spoke to COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy, about how the company’s immune-modifying nanoparticles work, how the approach preserves the immune response, and its partnership with Takeda focused on celiac disease.
What this episode covers
COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy discuss how the company’s immune-modifying nanoparticles work, how the approach preserves the immune response, and its partnership with Takeda focused on celiac disease.
NOW PLAYING
Teaching Tolerance to Address Autoimmune Diseases
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m